Ind-Swift Laboratories sees 35% CDMO revenue mix in H2 FY27

Ind-Swift Laboratories Limited expects contract development and manufacturing organisation (CDMO) products to account for about 35% of revenue as Ibuprofen revenue is estimated at Rs 40 crore to Rs 45 crore in H2 FY27, versus approximately Rs 15 crore to Rs 16 crore supplied in H1 FY27.

How much Ibuprofen revenue does Ind-Swift Laboratories expect in H2 FY27?

Ind-Swift Laboratories estimates Rs 40 crore to Rs 45 crore of Ibuprofen revenue in H2 FY27, comprising Rs 20 crore in Q3 FY27 and about Rs 20 crore to Rs 25 crore in Q4 FY27. Management said commercial supplies started after the Ibuprofen site variation was approved. The product contributed approximately Rs 15 crore to Rs 16 crore in H1 FY27, making the second-half estimate substantially higher than first-half supplies.

Management said Ibuprofen should start taking pace from Q3 FY27, while Macrogol and Clarithromycin are other contracted products expected to contribute in coming periods. Ind-Swift Laboratories did not provide a separate full-year FY27 revenue target for Ibuprofen beyond the Q3 and Q4 estimates.

The projected Ibuprofen ramp sits within Ind-Swift Laboratories’ broader FY27 guidance of more than 50% revenue growth. H1 FY27 operating revenue was Rs 420.97 crore, up 35.79% year on year from Rs 310.02 crore, and management said it was comfortable with the full-year projection.

What does a 35% CDMO mix mean for Ind-Swift Laboratories?

Ind-Swift Laboratories expects contract manufacturing to account for about 35% of revenue and own products for about 65% as its quarterly CDMO revenue grows. Management presented this as an expected mix, rather than a reported H2 FY27 outcome, and said both contract manufacturing and own-product revenue should increase.

In Q2 FY27, Ind-Swift Laboratories reported approximately Rs 190 crore of export revenue, comprising about Rs 65 crore from CDMO and Rs 125 crore from own-branding products. CDMO therefore represented roughly one-third of quarterly export revenue, while own-branding products represented about two-thirds, broadly consistent with management’s expected 35:65 mix.

The overall business remains export-led. Management said exports generated approximately 83% of H1 FY27 revenue and domestic turnover generated 17%, while its forward expectation is around 80% exports and 20% domestic sales. In the Q2 FY27 presentation, own brands contributed 55.75% of total sales and contract manufacturing contributed 26.99%.

Which products are supporting Ind-Swift Laboratories’ CDMO growth?

Ind-Swift Laboratories identified Ibuprofen, Macrogol and Clarithromycin as key products in the CDMO ramp, but their commercial status differs. Ibuprofen is being supplied following site-variation approval, whereas Clarithromycin remains dependent on European approval before batches can start.

For Macrogol, management said Ind-Swift Laboratories developed the product under its partnership with Aerotex. For Ibuprofen, Viatris shared the technology, after which Ind-Swift Laboratories developed the product, supplied stability data and supported the site-variation filing. The approved Ibuprofen variation underpins the Rs 20 crore Q3 FY27 estimate.

Clarithromycin dry suspension has completed commercial validation, but its European customer has filed a variation that remained pending at the time of the Q2 FY27 call. Management said batches would initiate once approval is received, so it did not identify Clarithromycin as current booked revenue.

Atorvastatin plus Ezetimibe is another material product contributor. Management said revenue from this molecule increased to approximately Rs 58 crore in Q2 FY27 from approximately Rs 25 crore in Q1 FY27, and clarified that its arrangement with Tiefenbacher relates to the combination product rather than Atorvastatin alone.

Can Ind-Swift Laboratories meet higher supplies with current capacity?

Ind-Swift Laboratories said the Derabassi facility, where it conducts most CDMO business, was operating at 70% to 75% capacity utilisation. Management also said current Derabassi capacity would be sufficient for the FY28 revenue scale raised by an analyst, although it did not disclose a facility-level revenue capacity figure.

The company has acquired land adjacent to Derabassi, obtained the required approvals and started warehouse construction. Management expects to shift the warehouse outside the existing facility in 10 to 12 months, a move intended to support export volumes and release space at the operating location.

At the Jammu/Samba plant, utilisation was also 70% to 75% while expansion work progresses. Ind-Swift Laboratories said its Rs 45 crore Samba upgrade to European Union Good Manufacturing Practice (EU-GMP) and Pharmaceutical Inspection Co-operation Scheme (PIC/S) standards remains on schedule and is intended to support topical and oral formulation exports.

Management expects a visit from Brazil’s ANVISA regulator in the last quarter and said PIC/S European approval could occur sometime next year. Those regulatory timelines are management expectations and remain subject to inspection and approval processes.

How does the CDMO ramp fit Ind-Swift Laboratories’ profit plan?

Ind-Swift Laboratories’ CDMO increase coincides with higher reported profitability in Q2 FY27. Operating revenue rose 50.15% year on year to Rs 234.89 crore, operating earnings before interest, tax, depreciation and amortisation (EBITDA) rose to Rs 42.33 crore from Rs 8.55 crore, and operating EBITDA margin reached 18.02%.

Raw-material expense declined to 45.15% of Q2 FY27 revenue from 49.38% a year earlier. Management attributed the movement to product-mix optimisation and operating leverage, while profit after tax rose to Rs 31.03 crore and the profit after tax margin reached 13.21%.

For H1 FY27, operating EBITDA was Rs 75.65 crore and the EBITDA margin was 17.97%, up 1,254 basis points year on year. Management said its internal target was 22%, expected a 19% to 20% margin in the next quarter as revenue rises, and anticipated a blended FY27 margin above 19%; these are management expectations rather than formal revised guidance.

Conclusion

The Ibuprofen schedule is the clearest disclosed driver of Ind-Swift Laboratories’ expected 35% CDMO revenue mix. The Rs 40 crore to Rs 45 crore H2 FY27 estimate is well above the Rs 15 crore to Rs 16 crore supplied in H1 FY27, while Q2 FY27 CDMO revenue of about Rs 65 crore within Rs 190 crore of exports shows that contracted products already have a material role.

Next, investors can watch the Rs 20 crore Ibuprofen estimate for Q3 FY27, the Rs 20 crore to Rs 25 crore Q4 FY27 projection, and the pending European variation for Clarithromycin. Management also plans to complete the Derabassi warehouse shift in 10 to 12 months and expects Samba’s PIC/S European approval sometime next year, subject to regulatory review.